CL2021001330A1 - Nuevos compuestos heterocíclicos - Google Patents
Nuevos compuestos heterocíclicosInfo
- Publication number
- CL2021001330A1 CL2021001330A1 CL2021001330A CL2021001330A CL2021001330A1 CL 2021001330 A1 CL2021001330 A1 CL 2021001330A1 CL 2021001330 A CL2021001330 A CL 2021001330A CL 2021001330 A CL2021001330 A CL 2021001330A CL 2021001330 A1 CL2021001330 A1 CL 2021001330A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic compounds
- compounds
- new heterocyclic
- new
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I): en donde A, B, L, X, R1, R2, R3 y R4 son, como se describen en la presente, composiciones que incluyen los compuestos, procesos para elaborar los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18207725 | 2018-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001330A1 true CL2021001330A1 (es) | 2021-10-29 |
Family
ID=64453331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001330A CL2021001330A1 (es) | 2018-11-22 | 2021-05-20 | Nuevos compuestos heterocíclicos |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20210387999A1 (es) |
| EP (1) | EP3883936B1 (es) |
| JP (1) | JP7444882B2 (es) |
| KR (1) | KR20210094540A (es) |
| CN (1) | CN113166170A (es) |
| AR (1) | AR117139A1 (es) |
| AU (1) | AU2019383500B2 (es) |
| BR (1) | BR112021009348A2 (es) |
| CA (1) | CA3119506A1 (es) |
| CL (1) | CL2021001330A1 (es) |
| CO (1) | CO2021007056A2 (es) |
| CR (1) | CR20210247A (es) |
| DK (1) | DK3883936T3 (es) |
| ES (1) | ES2955037T3 (es) |
| FI (1) | FI3883936T3 (es) |
| HR (1) | HRP20231083T1 (es) |
| HU (1) | HUE062913T2 (es) |
| IL (1) | IL283333B2 (es) |
| LT (1) | LT3883936T (es) |
| MA (1) | MA55131B1 (es) |
| MX (1) | MX2021005714A (es) |
| PE (1) | PE20211870A1 (es) |
| PH (1) | PH12021551167A1 (es) |
| PL (1) | PL3883936T3 (es) |
| PT (1) | PT3883936T (es) |
| RS (1) | RS64579B1 (es) |
| SG (1) | SG11202104206SA (es) |
| SI (1) | SI3883936T1 (es) |
| TW (1) | TWI825227B (es) |
| UA (1) | UA128505C2 (es) |
| WO (1) | WO2020104494A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| EP4474017A3 (en) | 2018-08-13 | 2025-02-26 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| WO2021048242A1 (en) * | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
| WO2022057928A1 (zh) * | 2020-09-18 | 2022-03-24 | 上海医药集团股份有限公司 | 一种羰基杂环类化合物及其应用 |
| EP4284365A4 (en) | 2021-01-29 | 2024-12-18 | Cedilla Therapeutics, Inc. | CDK2 INHIBITORS AND METHODS OF USE THEREOF |
| EP4358954A4 (en) | 2021-06-26 | 2025-09-03 | Cedilla Therapeutics Inc | CDK2 INHIBITORS AND METHODS OF USE THEREOF |
| US20250170101A1 (en) * | 2021-12-29 | 2025-05-29 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain and related conditions |
| EP4457213A4 (en) | 2021-12-29 | 2025-12-17 | Psy Therapeutics Inc | INHIBITION OF MONOACYLGLYCEROL LIPASE (MAGL) |
| WO2023130043A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety |
| WO2023144160A1 (en) * | 2022-01-25 | 2023-08-03 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| EP4543870A1 (en) * | 2022-06-24 | 2025-04-30 | F. Hoffmann-La Roche AG | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
| WO2024033277A1 (en) | 2022-08-08 | 2024-02-15 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| EP4568968A1 (en) * | 2022-08-11 | 2025-06-18 | Remynd N.V. | (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders |
| EP4590673A1 (en) * | 2022-09-20 | 2025-07-30 | F. Hoffmann-La Roche AG | Fluorescent probes for magl |
| KR20250092179A (ko) * | 2022-10-24 | 2025-06-23 | 에프. 호프만-라 로슈 아게 | 모노아실글리세롤 리파아제(magl) 억제제로서의 헤테로사이클릭 화합물 |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
| WO2025068347A1 (en) | 2023-09-28 | 2025-04-03 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| WO2025153656A1 (en) | 2024-01-19 | 2025-07-24 | F. Hoffmann-La Roche Ag | Heterocyclic inhibitors of monoacylglycerol lipase (magl) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| WO2011029804A1 (en) | 2009-09-10 | 2011-03-17 | F. Hoffmann-La Roche Ag | Inhibitors of jak |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| WO2016158956A1 (ja) * | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | 複素環化合物 |
| US10407407B2 (en) | 2015-05-21 | 2019-09-10 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as PAD4 inhibitors |
| CN107849017B (zh) | 2015-07-31 | 2021-03-30 | 辉瑞公司 | 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物 |
| WO2017087858A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2021048241A1 (en) * | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | Radiolabeled compounds |
-
2019
- 2019-11-20 CN CN201980077284.5A patent/CN113166170A/zh active Pending
- 2019-11-20 UA UAA202103201A patent/UA128505C2/uk unknown
- 2019-11-20 AU AU2019383500A patent/AU2019383500B2/en active Active
- 2019-11-20 CR CR20210247A patent/CR20210247A/es unknown
- 2019-11-20 PE PE2021000714A patent/PE20211870A1/es unknown
- 2019-11-20 IL IL283333A patent/IL283333B2/en unknown
- 2019-11-20 EP EP19809026.8A patent/EP3883936B1/en active Active
- 2019-11-20 BR BR112021009348-6A patent/BR112021009348A2/pt unknown
- 2019-11-20 LT LTEPPCT/EP2019/081870T patent/LT3883936T/lt unknown
- 2019-11-20 HR HRP20231083TT patent/HRP20231083T1/hr unknown
- 2019-11-20 PT PT198090268T patent/PT3883936T/pt unknown
- 2019-11-20 MA MA55131A patent/MA55131B1/fr unknown
- 2019-11-20 DK DK19809026.8T patent/DK3883936T3/da active
- 2019-11-20 ES ES19809026T patent/ES2955037T3/es active Active
- 2019-11-20 MX MX2021005714A patent/MX2021005714A/es unknown
- 2019-11-20 SG SG11202104206SA patent/SG11202104206SA/en unknown
- 2019-11-20 JP JP2021528972A patent/JP7444882B2/ja active Active
- 2019-11-20 PL PL19809026.8T patent/PL3883936T3/pl unknown
- 2019-11-20 FI FIEP19809026.8T patent/FI3883936T3/fi active
- 2019-11-20 RS RS20230788A patent/RS64579B1/sr unknown
- 2019-11-20 CA CA3119506A patent/CA3119506A1/en active Pending
- 2019-11-20 KR KR1020217015287A patent/KR20210094540A/ko active Pending
- 2019-11-20 SI SI201930619T patent/SI3883936T1/sl unknown
- 2019-11-20 WO PCT/EP2019/081870 patent/WO2020104494A1/en not_active Ceased
- 2019-11-20 HU HUE19809026A patent/HUE062913T2/hu unknown
- 2019-11-21 AR ARP190103417A patent/AR117139A1/es unknown
- 2019-11-21 TW TW108142267A patent/TWI825227B/zh active
-
2021
- 2021-05-20 US US17/325,934 patent/US20210387999A1/en active Pending
- 2021-05-20 CL CL2021001330A patent/CL2021001330A1/es unknown
- 2021-05-21 PH PH12021551167A patent/PH12021551167A1/en unknown
- 2021-05-28 CO CONC2021/0007056A patent/CO2021007056A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| CO2021002382A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| CL2021000361A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
| CO2020009567A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) de oxazina | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| CO2022002336A2 (es) | Compuestos heterocíclicos | |
| CO2023016204A2 (es) | Inhibidores de nlrp3 | |
| CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
| UY37487A (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| CO2022002339A2 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
| CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| MX2022003023A (es) | Compuestos heterociclicos. | |
| CL2025001372A1 (es) | Derivados de triazinona como inhibidores de nlrp3. | |
| BR112013028368A2 (pt) | novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona | |
| CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 | |
| UY38943A (es) | Nuevas heteroaril piperidiniletanonas sustituidas de 6 miembros | |
| CL2021000486A1 (es) | Derivados de heteroarilo bicíclicos | |
| UY38940A (es) | Nuevas piridiniloxi piperidiniletanonas sustituidas |